Delivery Order SPE2DB24D6041-SPE2DB25FKCMR
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,221.14 on August 25, 2025, for the supply of Estradiol 0.06% 1.25G Gel Pump in 37.5GM quantity. The contract is a firm fixed-price delivery order with an ultimate completion date of August 26, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation, reflecting the company's...
- The Defense Logistics Agency awarded a delivery order valued at $1,767.72 to AmerisourceBergen Drug Corp for Estradiol 0.06% 1.25G Gel Pump (37.5GM) on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,938.68, is for the delivery of Estradiol 0.06% 1.25G Gel Pump, 37.5GM. It is a firm-fixed-price delivery order contract with a completion date of January 24, 2025. The contract is not designated as a set-aside and was competitively awarded. Amerisourcebergen holds a larger $999,999,999...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Estradiol 0.06% 1.25g Gel Pump 37.5g. The contract has a ceiling value of $1,134.24 and a completion date of January 14, 2025. It is a firm fixed-price contract, and no set-aside designation was used. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 through...
- This is a federal contract award by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,140.33, is a delivery order for the supply of Estradiol 0.06% 1.25G Gel Pump 37.5GM, with a completion date of February 11, 2025. This award is not designated as a set-aside contract. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- The federal contract award SPE2DB20D1110|SPE2DB24FK54L was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to supply 37.5 gram pumps of 0.06% estradiol gel. The $1,933.33 firm-fixed-price delivery order has a completion date of September 18, 2024 and is not designated as a set-aside contract. Amerisourcebergen holds a larger indefinite delivery contract (IDC) valued up to $999,999,999 with DLA Troop Support Medical through December...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA), a defense agency, to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Estradiol 0.06% 1.25g gel pump, 37.5g, with a total ceiling value of $1,288.29. The contract type is firm fixed price, and the ultimate completion date is May 21, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00, which provides...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Estradiol 0.01% Cream in 42.5 gram quantities. This firm fixed-price delivery order, valued at $1,255.56, represents a non-competitive set-aside transaction and is scheduled for completion by August 26, 2025. The pharmaceutical product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Estradiol 0.01% Cream (42.5GM) on July 22, 2025, with a ceiling value of $1,150.32 and an ultimate completion date of July 23, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's larger Indefinite Delivery...
- This federal contract award is a delivery order with a firm fixed price valued at $1,461.56, issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the supply of ESTROGEL 0.06% GEL 50GM, a pharmaceutical product, with a completion date of February 28, 2024. This delivery order is placed under a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by...
- SPE2DB24D6041Indefinite Delivery Contract
- SPE2DB24D6041-SPE2DB25FKCMRDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Estradiol 0.06% gel in 1.25-gram pump format (37.5-gram total) with a ceiling value of $1,452.40. This non-set-aside contract utilizes firm fixed price terms with an ultimate completion date of August 28, 2025, and is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction within the company's broader federal pharmaceutical supply portfolio. This award is a child contract issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical vendor for federal medical procurement across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's federal contract awards demonstrate extensive capability in delivering a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains, with DLA planning to expand pharmaceutical prime vendor capabilities through Generation V regional contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 8/27/25 |